Qurient, a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organisation dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, have entered into a license agreement to develop and commercialise telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.
Qurient Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors
Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors
SEONGNAM-SI, South Korea--(BUSINESS WIRE)--Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for Q901, a small molecule oncology drug candidate targeting cyclin dependent kinase 7 (CDK7).
SEONGNAM-SI, Korea--(BUSINESS WIRE)--Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company in Korea, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for Q702, orally available immuno-oncology therapeutic small molecule targeting Axl, Mer and CSF1 receptor tyrosine kinases.
SEONGNAM-SI, Korea--(BUSINESS WIRE)--Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company in Korea, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for Q702, orally available immuno-oncology therapeutic small molecule targeting Axl, Mer and CSF1 receptor tyrosine kinases.